CRUSH-IT: Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain Injury

Sponsor
Kessler Foundation (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05716048
Collaborator
(none)
60
2
60

Study Details

Study Description

Brief Summary

New learning and memory impairment (NLMI) is a common and devastating manifestation of TBI associated with substantial life burdens. Persons with moderate to severe TBI have shown improvement in NLM for prose material (e.g. story) as well as beneficial changes in default-mode network (DMN) activation during list-learning19 following treatment with the Kessler Foundation modified Story Memory Technique® (KF-mSMT®). Benefits, however, were moderate and did not yield downstream improvements in daily life. It is thus critical to examine other approaches to complement the KF-mSMT® for robustly managing NLMI in TBI. The proposed RCT will be the first to include aerobic exercise training (AET) as a highly-promising complement to the KF-mSMT® for robustly managing NLMI, examining impact on NLM, its neural correlates, and daily life in NLM impaired persons with moderate-to-severe TBI. We thus propose a two-arm, parallel group, double-blind RCT comparing the effects of the KF-mSMT+AET with the KF-mSMT+S/T (active control condition) on NLM (Aim 1), hippocampal MRI (Aim 2), and daily life outcomes (Aim 3). 60 NLM impaired persons with moderate-to-severe TBI will be randomized to one of 2 conditions (30 per condition). Each condition will take place 3 days per week for 12 weeks and will be supervised by KF personnel. Participants will be blinded as to the intent of the conditions. We will further explore baseline predictors of clinically meaningful changes in NLM for those completing the KF-mSMT + AET condition (Exploratory Aim 4). If successful, this trial will position combinatory KF-mSMT and AET within the clinician's arsenal for robustly managing NLMI in persons with TBI. By augmenting the effects of KF-mSMT with AET, this treatment aims to exert a powerful countermeasure to TBI-related NLMI, and ultimately help those with TBI-related NLMI return to the workforce, independently manage their everyday lives, and maintain optimal quality of life. Additionally, while rigorously designed to answer the scientific question of the relative benefit of AET with the KF-mSMT, the proposed study is will likely provide some level of benefit to all study participants.

If successful, this trial will provide Class I evidence of combined KF-mSMT and AET for rehabilitating NLMI in TBI, based on standards published for therapeutic trials by the American Academy of Neurology, thus positioning such an approach within the clinician's arsenal for robustly managing NLMI. By augmenting the effects of KF-mSMT with AET, we anticipate this treatment will ultimately help those with TBI-related NLMI return to the workforce, independently manage their everyday lives, and maintain optimal quality of life.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: KF-mSMT Plus Aerobic Exercise Training
  • Behavioral: KF-mSMT Plus Stretching Exercise Training
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Randomized Controlled Trial of Combined Cognitive Rehabilitation and Exercise Training for Learning and Memory in Persons With Moderate to Severe Traumatic Brain Injury
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Feb 28, 2028
Anticipated Study Completion Date :
Feb 28, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: KF-mSMT Plus Aerobic Exercise Training

Participants will undergo 12 weeks of supervised aerobic cycling exercise training. During the last 8 weeks of cycling exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.

Behavioral: KF-mSMT Plus Aerobic Exercise Training
Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week

Active Comparator: KF-mSMT Plus Stretching Exercise Training

Participants will undergo 12 weeks of supervised stretching and toning exercise training. During the last 8 weeks of stretching exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.

Behavioral: KF-mSMT Plus Stretching Exercise Training
Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week

Outcome Measures

Primary Outcome Measures

  1. Change in California Verbal Learning Test-3 Performance [From 0 to 12 weeks]

    This is a test of new learning and memory

Secondary Outcome Measures

  1. Change in hippocampal volume [From 0 to 12 weeks]

    This involves a structural MRI scan wherein the volume of the bilateral hippocampi will be measured.

  2. Change in hippocampal activation [From 0 to 12 weeks]

    This involves an fMRI list-learning task wherein activation of the hippocampus during encoding and recall will be measured

  3. Change in hippocampal resting-state functional connectivity [From 0 to 12 weeks]

    This involves a resting-state fMRI paradigm wherein connectivity between the hippocampus and other brain regions that are important for learning and memory will be measured.

  4. Change in Everyday Memory Simulations Performance [From 0 to 12 weeks]

    This multi-component test examines aspects of memory that are relevant to daily life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age between 18-65 to control for age related brain changes

  • Diagnosis of moderate-to-severe TBI based on TBIMS criteria at least one year prior to enrollment

  • Having no to low substance use / involvement (drug/alcohol) as documented via ASSIST

  • Being insufficiently physically active based on a Godin Leisure-Time Exercise Questionnaire Health Contribution Score of <14

  • Having a proficiency in the English language

  • Being right handed to control for brain organization

  • Having chronic medical conditions (e.g. diabetes) in addition to TBI will require approval to participate from a physician, consistent with PAR-Q+.

  • Having an in-tact ability to follow directions based on the Telephone Interview for Cognitive Status (TICS-M) (i.e., TICS-M scores of ≥18)

  • Demonstrating new learning and memory impairment based on Open-Trial Selective Reminding Task (OT-SRT) scores at least 1.5 standard deviations below healthy controls (8+ trials to reach criterion)

Exclusion Criteria:
  • Regularly taking steroids & benzodiazapines to control for medications effects

  • Having a history of neurological disorders beyond TBI

  • Having a history of severe mental illness (e.g., schizophrenia, bipolar, severe major depression)

  • Having metal in the body, claustrophobia, and other risk factors that would make MRI scanning unsafe.

  • Having moderate or high risk for exercise training contraindications (e.g. diabetes), defined as ≥1 YES on pages 2-3 of the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+)

  • Having significantly impaired vision by scotomas (corrected vision in worse eye worse than 20/60), diplopia, or nystagmus.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Kessler Foundation

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Brian Sandroff, Senior Research Scientist, Kessler Foundation
ClinicalTrials.gov Identifier:
NCT05716048
Other Study ID Numbers:
  • R-1195-22
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2023